BDX · News · 20260806N
Revenue Performance and Mix
BECTON DICKINSON & CO · 2026-08-06 · Importance 43 · Surprise 32 · No source text
Third-quarter fiscal 2026 revenue was $4.983 billion, up 5.4% as reported and 4.4% on an FX-neutral basis year over year. Growth was broad-based across BD Medical Essentials, Connected Care, BioPharma Systems, and Interventional. Interventional was identified as the primary segment growth driver, while biologic drug delivery and advanced patient monitoring also contributed to revenue momentum.
Key facts
- Q3 revenue: $5.0 billion, increased 5.4% as reported and 4.4% FXN. source
- Worldwide revenues for the quarter were $4.983 billion, a 5.4% increase from the prior-year period. source
- Reported Q3 revenue of $4.98 billion for the quarter ended June 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +5.1% | Worldwide revenues for the quarter were $4.983 billion, a 5.4% increase from the prior-year period. |